share_log

藥明康德:董事會會議召開日期

WUXI APPTEC: Date of Board Meeting

HKEX ·  Oct 14 05:01

Summary by Moomoo AI

無錫藥明康德新藥開發股份有限公司(「药明康德」)宣佈將於2024年10月28日(星期一)召開董事會會議。會議的主要目的是考慮及批准本集團截至2024年9月30日止九個月的第三季業績及其發佈。董事會成員包括執行董事李革博士、陳民章博士、胡正國先生、楊青博士及張朝暉先生;非執行董事童小幪先生及吳亦兵博士;以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、詹智玲女士及馮岱先生。此次會議將對外界透露公司近期的財務表現,對投資者而言是一個重要的信息披露時刻。
無錫藥明康德新藥開發股份有限公司(「药明康德」)宣佈將於2024年10月28日(星期一)召開董事會會議。會議的主要目的是考慮及批准本集團截至2024年9月30日止九個月的第三季業績及其發佈。董事會成員包括執行董事李革博士、陳民章博士、胡正國先生、楊青博士及張朝暉先生;非執行董事童小幪先生及吳亦兵博士;以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、詹智玲女士及馮岱先生。此次會議將對外界透露公司近期的財務表現,對投資者而言是一個重要的信息披露時刻。
Wuxi Apptec announced that it will convene a board of directors meeting on Monday, October 28, 2024. The main purpose of the meeting is to consider and approve the third-quarter performance of the group for the nine months ending September 30, 2024, and its release. Board members include executive directors Dr. Li Ge, Dr. Chen Minzhang, Mr. Hu Zhengguo, Dr. Yang Qing, and Mr. Zhang Zhaohui; non-executive directors Mr. Tong Xiaoming and Dr. Wu Yibing; as well as independent non-executive directors Ms. Lu Shaohua, Dr. Yu Wei, Dr. Zhang Xin, Ms. Zhan Zhiling, and Mr. Feng Dai. This meeting will disclose the company's recent financial performance to the public, making it an important moment of information disclosure for investors.
Wuxi Apptec announced that it will convene a board of directors meeting on Monday, October 28, 2024. The main purpose of the meeting is to consider and approve the third-quarter performance of the group for the nine months ending September 30, 2024, and its release. Board members include executive directors Dr. Li Ge, Dr. Chen Minzhang, Mr. Hu Zhengguo, Dr. Yang Qing, and Mr. Zhang Zhaohui; non-executive directors Mr. Tong Xiaoming and Dr. Wu Yibing; as well as independent non-executive directors Ms. Lu Shaohua, Dr. Yu Wei, Dr. Zhang Xin, Ms. Zhan Zhiling, and Mr. Feng Dai. This meeting will disclose the company's recent financial performance to the public, making it an important moment of information disclosure for investors.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more